FMT

Are you a researcher working with #FMT? Be sure to keep an eye out for our upcoming Superheroes Connect event on #FMT. You might just find you next collaborator! Register your interest here: https://t.co/fmYuUNeM7G https://t.co/CGdFlmKohI— Australasian Human Microbiome Research Network (@microbiome_net) November 7, 2021

alysis to describe the efficacy and safety of FMT for CDI in IBD and its impact on IBD outcomes. Methods: A systematic search of multiple databases including Embase, Scopus, and Web of Science was performed. Our primary analysis focused on pooled rate of CDI resolution after single and multiple FMTs in IBD patients. Additional analyses included rates of IBD-associated outcomes (flare, surgery, symptom improvement) after FMT. The random-effects model was used to calculate pooled rates. Results: Among 457 adult patients, 363 had CDI resolution after first FMT with a pooled cure rate of 78% [95% confidence interval (CI): 73%-83%; I2=39%]. Overall pooled rate cure rate with single and multiple FMTs was 88% (95% CI: 81%-94%; I2=73%). The pooled rate of an IBD flare after FMT was 26.8% (95% CI: 22.5%-31.6%; I2=9%) and of colectomy was 7.3% (95% CI: 4.7%-10.5%; I2=56%). Among 141 pediatric patients, 106 had CDI resolution after first FMT with pooled cure rate of 78% (95% CI: 58%-93%; I2=59%). Overall pooled cure rate with single and multiple FMTs was 77% (95% CI: 50%-96%; I2=63%). The pooled rate of an IBD flare after FMT was 10.8% (95% CI: 5.7%-18.5% I2=43%), and of colectomy was 10.3% (95% CI: 2.1%-30.2% I2=23%). Conclusions: FMT appears to be a highly effective therapy for preventing recurrent CDI in patients with IBD. Patients who fail a single FMT may benefit from multiple FMTs. R.T. and S.K.: concept, data interpretation drafting and revision of manuscript. T.S., D.Y., S.S., E.V.L., and D.S.P.: drafting and revision of manuscript. L.J.P.: literature search. The authors declare that they have nothing to disclose. Address correspondence to: Sahil Khanna, MBBS, MS, 200 First Street SW, Rochester, MN 55905 (e-mail: khanna.sahil@mayo.edu). Received April 27, 2021 Accepted October 10, 2021 Copyright © 2021 Wolters Kluwer Health, Inc. All rights reserved....

#IBS is a dilabitating condition. Faecal Microbiota Transplantation #FMT can cure it completely for 50% and partially for the rest. Administered in 5 mins. Frustrating it’s out of reach on #NHS. Hear #MagdyElSalhy: https://t.co/lTMM5Knof8 @my_ueg @GutsCharityUK @guardiannews pic.twitter.com/6LqoqG89Fx— Gattaldo (@Gattaldo) December 10, 2021

Fecal microbiota transplantation (FMT) is highly effective in recurrent Clostridioides difficile infection (CDI); increasing evidence supports FMT in severe or fulminant Clostridioides difficile infection (SFCDI). However, the multifactorial mechanisms that underpin the efficacy of FMT …

In recent years, the idea of the gut microbiota being involved in the pathogenesis of autism spectrum disorders (ASD) has attracted attention through numerous studies. Many of these studies report microbial dysregulation in the gut and feces of autistic ...

The human microbiome has a strong influence on metabolism and immunity. Learn about how the power of the microbiome may break the cycle of recurrent C. diff.

Our study looked at risk of #Cdiff w #vedolizumab vs #antiTNF in biologic-naive UC.🔑 Lower absolute risk but no different adjusted risk of Cdiff with vedo🔑 Lower adjusted risk of severe Cdiff with vedo (new data) pic.twitter.com/rdZYTTZYo3— Rahul S. Dalal, MD (@RahulSDalalMD) December 11, 2021

About the Microbiome THE MICROBIOME The human microbiome provides metabolic and synthetic functions essential to the human health, including regulating the immune system and aiding in digestion. It also provides protection against colonization and invasion by potential microbial pathogens. Through a complex network of interacting microbes, the microbiome directly or indirectly affects

With the rising rates of Clostridioides (Clostridium) difficile infection (CDI) in children, recognizing the limitations of CDI-directed antibiotic therapy, especially in recurrent CDI (rCDI), is important. Fecal microbiota transplantation (FMT), which directly targets the underlying gut dysb …

Recurrent Clostridioides difficile infection (rCDI) is a frustrating condition that may affect a person's quality of life for months. Microbiome-based therapy such as fecal microbiota transplantation (FMT) has been effective for the treatment of rCDI by correcting the imbalance of the gut microbiota …

Fecal microbiota transplantation (FMT) has gained popularity as an effective therapeutic option for Clostridioides difficile infection (CDI). Since its FDA recognition as a treatment modality for recurrent CDI in 2013, screening protocols for FMT donor stool have been in flux. However, extens …

Fecal microbiota transplantation (FMT) is an efficient treatment for recurrent Clostridioides difficile infection and currently investigated as a treatment for other intestinal and systemic diseases. Better understanding of the species potentially transferred in FMT is needed. We isolated fro …

Shared insight on the process to gain access to fecal microbiota transplant for patients with clostridium difficile infection.

Dr. Cathy Williams knew something wasn't right. The veterinarian had felt off for weeks after her 2014 trip to Madagascar.

A focused discussion on the barriers to fecal microbiota transplant for patients with clostridium difficile infection.

Teena Chopra, MD, MPH, professor of infectious diseases at Wayne State University, explains what the gut-brain axis is and how microbiome impacts this connection.

The findings suggest a way to help patients heal from life-threatening C. difficile infections.

Findings suggest way to help patients heal from dangerous C. difficile. New research from the University of Virginia School of Medicine sheds light on why a fecal transplant can benefit patients with dangerous recurrent C. difficile infections – and suggests a way to improve patient outcomes.

GID-MT566 Faecal microbiota transplant for recurrent Clostridioides difficile infection

1. Our results are similar to @jfcryan lab on the beneficial effect of #heterochronic #FMT on #cognition (https://t.co/uoBBqIdTIH), but we use a shorter paradigm exploiting a pretreatment with #antibiotics. pic.twitter.com/XsN8rQIDWs— Omar Mossad (@OmarMglia) December 20, 2021

Nature Aging - The gut microbiome can change with age and influence aging-related diseases systemically, including in the brain. The authors show that rejuvenation of the gut microbiome by fecal...

#FecalMicrobiotaTransplant & #metabolomics link #aging-related #microbiome remodeling & #cognitive decline in miceImpairment rescued by #FMT from younger mice. #Microbial #metabolite δ-valerobetaine linked to declinehttps://t.co/zIhJtBQnoD#neurosciences @Halsin @NatureAging pic.twitter.com/NrGTeJBl4F— DDNews Online (@DDNewsOnline) December 20, 2021

Such great work led by @ironicbonding. More evidence that #FMT has many uses as a model of microbial community metabolism that we can’t leave behind once the commercial microbiome products are approved. https://t.co/oqrZivZ9qP— Mike (@MikeWoodworthMD) December 20, 2021

Fecal microbiota transplantation may be a safe and effective therapeutic intervention for AD patients, associated with transfer of specific microbial species from the donors to the patients.

Recent publications demonstrate that SARS-CoV-2 may undergo prolonged shedding in stool, and that gut microbiome perturbations associate with COVID-19 severity.1 2 Faecal microbiota transplant (FMT) restores a damaged gut microbiome and may impact on immune responses,3 including in the respiratory system (‘gut–lung axis’)4; such microbiome-immune signalling may result in lung-epithelial resistance to SARS-CoV-2.5 We describe two interesting cases of patients treated with FMT primarily to treat Clostridioides difficile infection (CDI), but which coincidentally were performed just before initial symptoms of coexisting COVID-19 (figure 1). Figure 1 Timeline of the procedures performed in patients with CDI, which coincidentally occurred during COVID-19 early stage infection. Created with BioRender.com. CDI, Clostridioides difficile infection; ESBL, extended-spectrum beta-lactamase, FMT, faecal microbiota transplant. Patient 1: an 80-year-old man with multiple comorbidities, including prior CDI, was admitted to hospital with pneumonia/sepsis. Following meropenem treatment, pneumonic features resolved, but CDI relapse occurred. Sequential vancomycin treatment and nasojejunal FMT were administered. On the day of FMT, he …

Autism spectrum disorder (ASD) comprises a group of neurodevelopmental disorders with a high prevalence in childhood. The gut microbiota can affect human cognition and moods and has a strong correlation with ASD. Microbiota transplantation, including faecal microbiota transplantation (FMT), probiotics, breastfeeding, formula feeding, gluten-free and casein-free (GFCF) diet and ketogenic diet therapy, may provide satisfying effects for ASD and its related various symptoms. For instance, FMT can improve the core symptoms of ASD and gastrointestinal symptoms. Probiotics, breastfeeding and formula feeding, and GFCF diet can improve gastrointestinal symptoms. The core symptom score still needs to be confirmed by large-scale clinical randomized controlled studies. It is recommended to use a ketogenic diet to treat patients with epilepsy in ASD. At present, the unresolved problems include which of gut the microbiota are beneficial, which of the microorganisms are harmful, how to safely and effectively implant beneficial bacteria into the human body, and how to extract and eliminate harmful microorganisms before transplantation. In future studies, large sample and randomized controlled clinical studies are needed to confirm the mechanism of intestinal microorganisms in the treatment of ASD and the method of microbial transplantation.

Shared insight on the phase 3 data behind RBX2660, a novel FMT therapy for patients with recurrent Clostridioides difficile infection.

Fecal microbiota transplantation (FMT) is an effective and safe treatment to treat recurrent Clostridioides difficile infection. It is essential to make every effort to perform FMT rigorously and based on scientific knowledge. Selection of the fecal microbiota donor is a key point of the process to …

Experts reflect on the barriers to utilizing fecal microbiota transplantation therapy in Clostridioides difficile infection.